Revised Aug. 17, 2016
Now available at www.nacblood.ca
Inventory Data - Canadian Blood Services
- Aug. 11, 2016
The National Plan for the Management of Shortages of Labile Blood Components
- November 19, 2015
Recommendations for the Notification of Recipients of a Blood Component Recall
- July 14, 2015
Long-Acting Factor Category Related Products
- Criteria for Use - Alprolix and Eloctate, Jan. 18, 2016
The National Advisory Committee on Blood and Blood Products has commissioned the Knowledge Synthesis group at the Ottawa Hospital Research Institute (OHRI) to assess the currency of the following two clinical practice guideline recommendations using the Ottawa method’s qualitative signal detection approach:
- Guideline on the use of Intravenous Immune Globulin (IVIG) for 22 Neurologic conditions.
- Guideline on the use of Intravenous Immune Globulin (IVIG) for 18 Hematologic conditions.
The Ottawa method involves identification of qualitative and quantitative signals/triggers indicating the need of updating of any given systematic review.
The following documents will be posted soon:
- NAC’s statement on the equivalency of Cytomegalovirus (CMV) seronegative and CMV safe (leukoreduced) product
- NAC’s recommendations for the use of irradiated blood components in Canada
- Companion Document to: "RBC Transfusion: AABB Guideline"
- Group O Rh-Negative
- Massive Transfusion
- National Blood Shortages Plan
- New Direct Anticoagulants
- Prothrombin Complex Concentrates/PCC Videos
- Recipient Recall Notification
- S/D Plasma
- Criteria for Use - Alprolix and Eloctate
- Adverse Reaction Reporting Mechanisms